Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Marimed (MRMD) Other Operating Expenses (2016 - 2025)

Marimed (MRMD) has disclosed Other Operating Expenses for 13 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 7.78% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.0 million through Dec 2025, up 1.94% year-over-year, with the annual reading at $34.1 million for FY2025, 1.91% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $8.0 million at Marimed, down from $8.0 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $9.6 million in Q1 2025, with the low at $2.1 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is $6.5 million, with a median of $7.4 million recorded in 2023.
  • Peak annual rise in Other Operating Expenses hit 205.93% in 2021, while the deepest fall reached 11.49% in 2021.
  • Over 5 years, Other Operating Expenses stood at $3.7 million in 2021, then surged by 140.82% to $8.8 million in 2022, then decreased by 6.44% to $8.2 million in 2023, then fell by 10.21% to $7.4 million in 2024, then increased by 7.78% to $8.0 million in 2025.
  • According to Business Quant data, Other Operating Expenses over the past three periods came in at $8.0 million, $8.0 million, and $8.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.